Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkins Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia

Trial Profile

Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkins Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IRIS; Pharmacyclics
  • Most Recent Events

    • 31 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 05 Jan 2017 This trial was completed in Hungary (end date:2016-11-23), according to European Clinical Trials Database.
    • 28 Jan 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top